Skip to main content
. 2023 Apr 10;8(7):e165609. doi: 10.1172/jci.insight.165609

Figure 2. Clonal hematopoiesis is present in most patients prior to lung transplantation.

Figure 2

(A) Longitudinal samples from a prospective cohort of patients were tracked pretransplant (pre) through posttransplant. Variant allele frequencies are shown on log scale for each somatic variant over time, grouped by TP53, PPM1D, and ATM (DDR, left, red) DNMT3A, TET2, and ASXL1 (middle, blue), or other genes (right, black). (B) Proportion of lung transplantation recipients with any CH (top, blue) or DDR CH (bottom, red) based on lung disease diagnosis, pretransplantation immunosuppressive therapy, or presence of germline variant in surfactant or telomere maintenance genes. COPD, chronic obstructive lung disease; ILD, interstitial lung disease; IS, immunosuppressive therapy. (C) Whole exome sequencing in a subset of 52 lung recipients was interrogated for germline variants in genes associated with myeloid malignancies (DDX41), telomere biology disorders (RTEL1, TERT, PARN), or surfactant genes (SFTPC, SFTPA1, SFTPA2). Shown are pathogenic or uncertain significance germline variants (columns) versus somatic (clonal hematopoiesis) variants (rows).